JP6173298B2 - 治療薬としての肝細胞増殖因子模倣体 - Google Patents

治療薬としての肝細胞増殖因子模倣体 Download PDF

Info

Publication number
JP6173298B2
JP6173298B2 JP2014503898A JP2014503898A JP6173298B2 JP 6173298 B2 JP6173298 B2 JP 6173298B2 JP 2014503898 A JP2014503898 A JP 2014503898A JP 2014503898 A JP2014503898 A JP 2014503898A JP 6173298 B2 JP6173298 B2 JP 6173298B2
Authority
JP
Japan
Prior art keywords
hgf
ile
tyr
dihexa
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014503898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014511858A (ja
JP2014511858A5 (https=
Inventor
ダブリュウ ハーディング，ジョセフ
ダブリュウ ハーディング，ジョセフ
ダブリュウ ライト，ジョン
ダブリュウ ライト，ジョン
シー． ベノワ，キャロリーヌ
シー． ベノワ，キャロリーヌ
エイチ． カワス，リーン
エイチ． カワス，リーン
エイ． ウェイマン，ゲイリー
エイ． ウェイマン，ゲイリー
Original Assignee
ワシントン ステート ユニバーシティ
ワシントン ステート ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ワシントン ステート ユニバーシティ, ワシントン ステート ユニバーシティ filed Critical ワシントン ステート ユニバーシティ
Publication of JP2014511858A publication Critical patent/JP2014511858A/ja
Publication of JP2014511858A5 publication Critical patent/JP2014511858A5/ja
Application granted granted Critical
Publication of JP6173298B2 publication Critical patent/JP6173298B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
JP2014503898A 2011-04-02 2012-04-02 治療薬としての肝細胞増殖因子模倣体 Active JP6173298B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161471122P 2011-04-02 2011-04-02
US201161471124P 2011-04-02 2011-04-02
US61/471,124 2011-04-02
US61/471,122 2011-04-02
PCT/US2012/031815 WO2012138599A2 (en) 2011-04-02 2012-04-02 Hepatocyte growth factor mimics as therapeutic agents

Publications (3)

Publication Number Publication Date
JP2014511858A JP2014511858A (ja) 2014-05-19
JP2014511858A5 JP2014511858A5 (https=) 2015-05-14
JP6173298B2 true JP6173298B2 (ja) 2017-08-02

Family

ID=46969763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014503898A Active JP6173298B2 (ja) 2011-04-02 2012-04-02 治療薬としての肝細胞増殖因子模倣体

Country Status (8)

Country Link
US (3) US9150613B2 (https=)
EP (1) EP2709650B1 (https=)
JP (1) JP6173298B2 (https=)
CN (1) CN103582490B (https=)
AU (1) AU2012240424B2 (https=)
CA (1) CA2832113C (https=)
ES (1) ES2622385T3 (https=)
WO (1) WO2012138599A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048035A1 (en) 2001-12-07 2005-03-03 Fraser John K. Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
US20050095228A1 (en) 2001-12-07 2005-05-05 Fraser John K. Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
US9597395B2 (en) 2001-12-07 2017-03-21 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO2010021993A1 (en) 2008-08-19 2010-02-25 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in the treatment of the lymphatic system and malignant disease
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
WO2014052766A1 (en) * 2012-09-27 2014-04-03 Washington State University Hepatocyte growth factor mimics as therapeutic agents
US20170065638A1 (en) * 2014-02-10 2017-03-09 Cytori Therapeutics, Inc. Regenerative cell therapy for central nervous system (cns) disorders and ptsd
CN104788537B (zh) * 2015-03-31 2018-03-13 中国科学院长春应用化学研究所 一种四肽化合物及其制备方法和应用
US11021514B2 (en) * 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
CN106699868B (zh) * 2017-03-01 2019-11-15 牡丹江医学院 一种蛋白质及编码其的核苷酸序列
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
CN110716925B (zh) * 2019-09-05 2023-08-04 中电科大数据研究院有限公司 一种基于轨迹分析的跨境行为识别方法
US20230000943A1 (en) * 2021-06-29 2023-01-05 Synaptogenix, Inc. Method of inducing synaptogenesis by administering angiotensin and analogues thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE160585T1 (de) * 1992-09-18 1997-12-15 Us Gov Health & Human Serv Eine methode zur herstellung von hepatozytwachstumsfaktor und eine zelllinie
US5854388A (en) * 1993-06-24 1998-12-29 Washington State University Research Foundation Angiotensin IV peptides and receptor
US6777388B1 (en) * 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7192976B2 (en) 2002-12-21 2007-03-20 Angion Biomedica Corporation Small molecule modulators of hepatocyte growth factor (scatter factor) activity
WO2008005531A2 (en) * 2006-07-07 2008-01-10 Washington State University Research Foundation C-met receptor regulation by angiotensin iv (at4) receptor ligands
WO2011019400A2 (en) * 2009-08-12 2011-02-17 Angion Biomedica Corp. Enhancement of cellular transplantation using small molecule modulators hepatocyte growth factor (scatter factor) activity

Also Published As

Publication number Publication date
US8598118B2 (en) 2013-12-03
AU2012240424B2 (en) 2017-10-26
WO2012138599A2 (en) 2012-10-11
EP2709650A2 (en) 2014-03-26
JP2014511858A (ja) 2014-05-19
US9150613B2 (en) 2015-10-06
NZ616210A (en) 2015-07-31
US20140088004A1 (en) 2014-03-27
EP2709650B1 (en) 2017-02-08
ES2622385T3 (es) 2017-07-06
CN103582490B (zh) 2015-09-30
WO2012138599A3 (en) 2013-01-17
CA2832113A1 (en) 2012-10-11
HK1196075A1 (en) 2014-12-05
EP2709650A4 (en) 2015-04-22
US20130165392A1 (en) 2013-06-27
US20170049843A1 (en) 2017-02-23
CN103582490A (zh) 2014-02-12
CA2832113C (en) 2020-07-21
AU2012240424A1 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
JP6173298B2 (ja) 治療薬としての肝細胞増殖因子模倣体
ES2273849T3 (es) Composiciones farmaceuticas que comprenden compuestos ciclicos peptidometicos con giro beta.
US20140094413A1 (en) Hepatocyte growth factor (hgf) mimics as therapeutic agents
CN104427993B (zh) 用于治疗由缺氧和低气压造成的肺型高山病的药物组合物
JP6640725B2 (ja) ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
ES3057215T3 (en) Antagonist binding to dpep-1 for use in treating or preventing acute kidney injury or ischemia-reperfusion injury
TW201412325A (zh) 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療
US9051351B2 (en) Hepatocyte growth factor mimics as therapeutic agents
TWI740034B (zh) 治療癌症之肽
ES2313777T3 (es) Inhibidores de la neovascularizacion.
KR102532557B1 (ko) Dsg2 유래 펩타이드
US8138304B2 (en) Neural regeneration peptides and formulations thereof
NZ616210B2 (en) Hepatocyte growth factor mimics as therapeutic agents
HK1196075B (en) Hepatocyte growth factor mimics as therapeutic agents
JP4778507B2 (ja) 化学療法誘発末梢性ニューロパシーの治療のためのｉｌ６ｒ／ｉｌ６キメラ
Class et al. Patent application title: HEPATOCYTE GROWTH FACTOR (HGF) MIMICS AS THERAPEUTIC AGENTS Inventors: Joseph W. Harding (Pullman, WA, US) John W. Wright (Pullman, WA, US) Caroline C. Benoist (Nashville, TN, US) Leen H. Kawas (Pullman, WA, US) Gary A. Wayman (Pullman, WA, US) Assignees: WASHINGTON STATE UNIVERSITY
Kawas Development of therapeutics targeting the hepatocyte growth factor (HGF)/MET system
Walker Combinational treatment approach for traumatic spinal cord injury
HK40022338A (en) A biomimetic peptide and biodegradable delivery platform
CN1988914A (zh) 胞间通讯易化化合物的新医学用途
Heskamp Role of CXCL12 and CXCR4 in axonal regeneration of mature retinal ganglion cells

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150327

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150409

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20150515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170628

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170704

R150 Certificate of patent or registration of utility model

Ref document number: 6173298

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250